Key result
Venous Doppler profile improvement at day 5 was independently associated with a lower risk of 60-day readmission (HR 0.22; 95% CI 0.05-0.94; P=0.04) and death (HR 0.07; 95% CI 0.01-0.68; P=0.02).
Why the study?
Increased right atrial pressure in ADHF causes persistent kidney congestion, but a marker to guide optimal diuretic therapy is lacking.
Does intrarenal venous Doppler profile improvement predict reduced death and rehospitalization in patients with acute decompensated heart failure?
Cohort (n=72)
Blinded
Does intrarenal venous Doppler profile improvement predict reduced death and rehospitalization in patients with acute decompensated heart failure?
Hazard Ratio: 0.22 (95% CI 0.05–0.94)
p-value: p=0.04
Improvement in intrarenal venous Doppler profile during decongestion is a strong independent predictor of lower 60-day readmission and mortality in acute decompensated heart failure.
May support venous Doppler monitoring for risk stratification in ADHF; hypothesis-generating and should not yet change practice.
AIMS: An increase in right atrial pressure is a common feature of acute decompensated heart failure (ADHF). Such increased pressure leads to persistent kidney congestion. A marker to guide optimal diuretic therapy is missing. We aim to correlate intrarenal Doppler (IRD) ultrasound in ADHF patients with clinical outcomes to assess whether renal haemodynamic parameter changes are useful for monitoring kidney congestion. METHODS AND RESULTS: Between December 2018 and January 2020, ADHF patients requiring intravenous diuretic therapy for at least 48 h were considered for study selection. An IRD blinded examination was performed on Days 1, 3, and 5, and clinical and laboratory parameters were recorded. Venous Doppler profiles (VDP) were classified as continuous (C), pulsatile (P), biphasic (B), or monophasic (M) according to the congestion degree; B and M profiles were considered deranged. A VDP improvement (VDPimp) was defined as a change of ≥1 pattern degree or maintenance of C or P patterns. An arterial resistive index (RI) > 0.8 was considered elevated. Outcomes of death and rehospitalization were gathered at 60 days. Data were assessed by regression and Kaplan-Meier analyses. All 177 ADHF patients admitted were screened, and 72 were enrolled [27 females-median age 81 (76-87) years-median ejection fraction 40% (30-52)]. The VDP derangement decreased from 79.2% on Day 1 to 51.4% on Day 5 (P < 0.05). The RI elevation decreased from 60.6% on Day 1 to 43.1% on Day 5 (P < 0.05). At Day 5, VDPimp was registered in over half of the patients (59.7%). At Day 5, signs of congestion (dyspnoea/oedema/rales), fluid accumulation (pleural/peritoneal fluid), haematocrit, and brain natriuretic peptide improved (P > 0.05). After 60 days, 12 (16.7%) patients were readmitted and 9 (12.5%) died. The VDPimp was identified as the unique independent factor associated with readmission [Hazard Ratio (HR) 0.22, 95% (confidence interval) CI 0.05-0.94, P = 0.04] and death (HR 0.07, 95% CI 0.01-0.68, P = 0.02), with significantly better outcomes identified in VDPimp patients (log-rank test, P < 0.05). CONCLUSION: Decongestion may be associated with improvements in many clinical and instrumental parameters, but only VDPimp was associated with better clinical outcomes. The VDPimp should be incorporated in ad hoc ADHF clinical trials to better define its role in everyday practice.
No takes yet. Share an insight, caveat, or question.
Turrini et al. (2023) conducted a cohort in Acute Decompensated Heart Failure (n=72). Venous Doppler profile improvement (VDPimp) vs. No VDP improvement was evaluated on Readmission at 60 days (HR 0.22, 95% CI 0.05-0.94, p=0.04). Venous Doppler profile improvement at day 5 was independently associated with a lower risk of 60-day readmission (HR 0.22; 95% CI 0.05-0.94; P=0.04) and death (HR 0.07; 95% CI 0.01-0.68; P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: